Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Ligand’s Fourth Quarter Financial Results to be Reported February 3rd
Ligand Receives Milestone Payment from Merck
